Form 4: Director Todd Thomson Receives Actuate Therapeutics Options
Statement of Changes in Beneficial Ownership
Director Todd Thomson was granted 15,000 stock options in Actuate Therapeutics, Inc. with an exercise price of $2.42.
Summary
- Todd Thomson, a director at Actuate Therapeutics, Inc., was granted 15,000 stock options on May 21, 2026.
- The options have an exercise price of $2.42 per share.
- The options are set to vest in full on the first anniversary of the grant date, May 21, 2027.
- The options expire on May 21, 2036.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding director compensation with no material impact on the company's financial outlook.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
Negatives
- Dilutive impact of new option grants on existing shareholders.
Risks
- Market volatility affecting the value of the underlying common stock relative to the $2.42 exercise price.
Future Outlook
The filing does not provide forward-looking financial guidance, focusing solely on the disclosure of director equity compensation.
Management Comments
- Todd Thomson serves as a representative of Kairos Venture Investments, LLC on the Board of Actuate Therapeutics, Inc.
Industry Context
StockSavvy.ai notes that equity grants to board members are standard corporate governance practice in the biotechnology sector to ensure director alignment with company performance.
Comparison to Industry Standards
- The grant of stock options to non-executive directors is consistent with standard compensation packages for small-cap biotech firms.
- Vesting schedules of one year are common for director-level equity awards in the industry.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Compensation | Grant of 15,000 stock options to Director Todd Thomson. | 05/21/2026 | Standard alignment of director interests with shareholders. |
Related Party Transactions
- Todd Thomson serves as CFO/COO of Kairos Venture Investments, LLC, which holds an indirect pecuniary interest in the granted securities.
Stakeholder Impact
- Shareholders experience minor dilution from the issuance of new options.
Next Steps
- Vesting of options on May 21, 2027.
Key Dates
| Date | Description |
|---|---|
| 05/21/2026 | Grant date of stock options and date of earliest transaction. |
| 05/22/2026 | Date of filing. |
| 05/21/2027 | Vesting date for the 15,000 stock options. |
| 05/21/2036 | Expiration date of the stock options. |
Keywords
Actuate Therapeutics, ACTU, Form 4, Insider Trading, Stock Options, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.